RUBINSTEIN JULIE sold $1.0M of ADPT
RUBINSTEIN JULIE (President and COO) sold 35,228 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $29.73 ($28.93–$31.22, $1.05M total) across 4 trades over 2026-11-11 to 2026-11-13 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale adds a modest bearish signal, but the small size and pre‑arranged plan limit its material impact.
Market read
Primary relevance is to ADPT shareholders; broader market effect is negligible.
What to watch
The 10b5-1 plan pre‑arranged nature may mitigate negative interpretation.
Background
SEC Form 4 filing discloses an insider transaction by Adaptive Biotechnologies' President and COO.
Ticker impact
President and COO Julie Rubinstein sold 35,228 shares of Adaptive Biotechnologies for $1.05M via a 10b5-1 plan.
likely slight downward pressure as the market prices in the insider sale
C-suite insider sales, even modest in size, are often interpreted as a bearish signal by traders.
Market effects
Minimal impact on the biotech sector; isolated to ADPT.
No regional effect beyond the company's share price.
Limited global relevance.
Counterpoint
The sale could be a routine liquidity move unrelated to company outlook.
Key entities
- companyAdaptive Biotechnologies Corp
US‑listed biotech company (ticker ADPT).
- personJulie Rubinstein
President and COO of Adaptive Biotechnologies.



